Marizyme Announces European DuraGraft(R) Registry Results Presented at the European Association for Cardio-Thoracic Surgery (EACTS) 34th Annual Virtual Meeting

Author's Avatar
Oct 10, 2020
Article's Main Image

JUPITER, FL / ACCESSWIRE / October 9, 2020 / Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB:MRZM) is a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications. Today, Marizyme announced that results from its European DuraGraft Registry were presented on October 8, 2020 at the EACTS Annual Meeting.